RxDoctor Payments Data

Secily Bason-Mitchell, MD

Obstetrics · San Francisco, CANPI 1992872089

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 91.5% of the total across 129 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 12.4% — the pattern of someone who eats at a lot of different presentations.

$3,102in general payments, 2019–2025

Across 129 payments — averaging $24.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$385
  • Astellas Pharma US Inc$376
  • Biogen$351
  • Hologic Sales And Service, LLC$309
  • Mayne Pharma Commercial LLC$170
  • Avion Pharmaceuticals$148
  • plus $1K from 23 others

What the payments were for

  • Food & beverage$2,83791%
  • Education$2659%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,102 in reported general payments places this provider in the 80th percentile of 119 obstetrics providers in California.

See all obstetrics providers in California

Medicare billing

Part B allowed, 2024
$8,196
Medicare patients
28
Services billed
63

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EstringEstradiol20$10,768
Estradiol13$1,136

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEstring$66$10,76820 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 119 obstetrics providers in California.

Other obstetrics in San Francisco

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →